Compare CubeSmart (CUBE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Recursion Pharmaceuticals Inc — how do they compare? CubeSmart trades at $37.93 (market cap $8.45B), while Recursion Pharmaceuticals Inc trades at $4.35 (market cap $2.14B). The key difference: CubeSmart is far larger — about 3.9× Recursion Pharmaceuticals Inc's market cap, and CubeSmart pays a 5.65% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| CUBE | RXRX | |
|---|---|---|
Market Cap | $8.45B | $2.14B |
Volume | 2,879,532 | 30,789,535 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $6.79 |
52-Week Low | $35.36 | $2.84 |
Typical Hold Time | 89 Days | 23 Days |
Enterprise Value | $11.97B | $1.66B |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.97, up 1.99% on the day, with a bearish technical outlook as moving averages signal selling pressure. The company reported mixed Q2 2026 results, with an FFO miss but revenue beat, and maintains strong profitability with a 29.41% net income margin. Recent news highlights institutional accumulation, with firms like NewEdge Advisors and Deutsche Bank increasing stakes, while analyst consensus leans toward Hold with a $44.00 price target.
The stock offers a 5.4% dividend yield and trades below the consensus target, suggesting potential upside if operational improvements materialize. Risks include high leverage with $2.99B in long-term debt and sensitivity to real estate market cycles. Earnings growth in H2 2026 is critical for reversing the current bearish sentiment.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
